Gain Therapeutics, Inc. - GANX STOCK NEWS

Gain Therapeutics, a clinical-stage biotechnology company, announced that its CFO, Gene Mack, will participate in H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024. The event will feature a fireside chat and virtual one-on-one meetings. Attendees can watch the fireside chat starting at 7:00am ET through an on-demand webcast. A replay will be available on Gain Therapeutics' website under the Investors and Media section following the event. Gain Therapeutics is recognized for its work in developing allosteric small molecule therapies.

Gain Therapeutics announced the pricing of an $11.0 million public offering, consisting of 7,116,547 common shares at $1.35 per share and pre-funded warrants for 1,031,602 shares. The pre-funded warrants are exercisable immediately. Gain has also given the underwriter a 30-day option to purchase an additional 1,222,222 common shares. Titan Partners Group is the sole bookrunner. The offering is set to close around June 17, 2024, pending customary conditions. The proceeds will support clinical and nonclinical development of GT-02287 for neurodegenerative diseases and other corporate purposes. The securities are being offered via a prospectus supplement, which is available on the SEC's website.

Gain Therapeutics, a Nasdaq-listed company (GANX), announced a public offering of its common stock and pre-funded warrants. The offering's final terms will depend on market conditions. Gain plans to use the proceeds to further develop its lead candidate, GT-02287, aimed at treating neurodegenerative diseases like GBA1 Parkinson's disease, and for general corporate purposes. Titan Partners Group is the sole bookrunner for this offering. All securities will be offered by Gain under a previously filed shelf registration statement with the SEC.

Gain Therapeutics has announced that its late-breaking abstract on GT-02287, a clinical-stage GCase enhancer, has been accepted for presentation at the FENS Forum 2024 in Vienna. New data reveals improvements in cognitive performance in a preclinical model of GBA1 Parkinson’s disease. The presentation is scheduled for June 27, 2024, and will be delivered by Dr. Beatriz Calvo-Flores Guzman. The FENS Forum is Europe's largest neuroscience congress, encompassing both basic and translational research. This recognition could potentially highlight the innovative strides Gain Therapeutics is making in the biotechnology sector, particularly in treating neurodegenerative diseases.

Gain Therapeutics (Nasdaq: GANX) has released its Q1 2024 financial results, reporting positive developments despite a decrease in both R&D and G&A expenses. The company announced favorable outcomes from the SAD part of its Phase 1 GT-02287 trial, initiated the MAD portion, and presented promising data on neuroprotection in Parkinson’s models.

Key executive appointments were made, with Gene Mack as CFO and Jonas Hannestad as CMO. The company maintains a cash runway into 2025, supported by potential grant applications. Financially, R&D expenses decreased by $0.3M to $2.5M, and G&A expenses fell by $0.6M to $1.9M. Net loss per share improved to $0.22 from $0.43 YoY. Cash reserves dropped to $12.7M from $16.8M year-end 2023.

Gain Therapeutics announces positive results from the single ascending dose (SAD) part of the Phase 1 Clinical Trial of GT-02287, a novel GCase-targeting small molecule therapy for GBA1 Parkinson’s Disease. The trial showed GT-02287 was well tolerated with no serious adverse events, achieving appropriate plasma exposure levels. GT-02287 aims to slow or stop Parkinson's disease progression by treating the underlying cause. Preclinical data also showed promising results in restoring motor function and reducing neurodegeneration biomarkers.

Gain Therapeutics, Inc. appoints Gene Mack as CFO, bringing 25 years of experience in life sciences. Mack to lead financial strategies and advance lead drug candidate GT-02287 for Parkinson's disease.

Gain Therapeutics, Inc. appoints Dr. Jonas Hannestad as Chief Medical Officer, bringing extensive experience in CNS drug development. Dr. Hannestad will lead the advancement of GT-02287 program for Parkinson's disease. The Company also grants him an option to purchase 200,000 shares of common stock.

Gain Therapeutics, Inc. (Nasdaq: GANX) reports financial results for 2023, highlighting progress in developing small molecule therapies for Parkinson's disease. The company presented data on lead compound GT-02287, initiated Phase 1 clinical trials, and raised $10.1 million. However, increased R&D and G&A expenses led to a net loss of $22.3 million for 2023.